NYC’s Leading Integrative Health Care Center

Anti-Aging and Longevity Treatments Remember when you were in college and stayed up all night drinking beer, eating pizza, and partying; yet you still were able to attend class in the morning? How many of you could do that now?
Chronic Fatigue Syndrome (ME/CFS) is a complex neuroimmune disease that disrupts cellular energy production, immune regulation, and autonomic function — leaving millions of patients profoundly exhausted, cognitively impaired, and unable to sustain ordinary daily life, often for years without a satisfying diagnosis.
Americans estimated to have ME/CFS (CDC)
of ME/CFS patients remain undiagnosed or misdiagnosed
More common in women than men
Average delay from onset to correct diagnosis
Board-certified integrative medicine physician.
Chronic Fatigue Syndrome — formally designated Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) — is a serious, multi-system neuroimmune disease meeting the 2015 Institute of Medicine diagnostic criteria: six or more months of profound fatigue not improved by rest, post-exertional malaise, unrestorative sleep, and either cognitive impairment or orthostatic intolerance. It is associated with measurable dysfunction of the hypothalamic-pituitary-adrenal axis, mitochondrial energy metabolism, natural killer (NK) cell cytotoxic activity, and autonomic nervous system regulation. ME/CFS is not caused by deconditioning, psychological illness, or malingering; it represents a distinct pathophysiological syndrome requiring comprehensive biological investigation.
Chronic Fatigue Syndrome (ME/CFS) is not ordinary tiredness. It is a serious, systemic disease in which the body’s fundamental energy production and regulatory systems — the mitochondria, the immune system, the autonomic nervous system, and the hormonal HPA axis — fail to function in concert. Patients experience fatigue so severe that it can reduce their functional capacity by 50% or more, often confining them to bed for days at a time after even minimal exertion. Unlike the temporary fatigue that follows a stressful week or a sleepless night, ME/CFS fatigue does not recover with rest; it persists, and in many patients it worsens over time without appropriate intervention.
At the biological level, the central dysfunction in ME/CFS appears to involve impaired cellular energy production within the mitochondria — the organelles responsible for generating adenosine triphosphate (ATP), the molecule that powers every cell in the body. Research published in Nature Communications (2021) identified abnormalities in patients’ metabolic signatures consistent with a shift away from oxidative phosphorylation toward less efficient anaerobic energy pathways. Compounding this, the hypothalamic-pituitary-adrenal (HPA) axis — which coordinates the stress response via cortisol — shows characteristic blunted patterns in ME/CFS patients: low morning cortisol, flattened diurnal rhythm, and impaired cortisol response to stress. This leaves the body unable to mount adequate physiological responses to even modest demands.
Functional medicine recognised ME/CFS as a legitimate, biological condition long before mainstream medicine fully acknowledged it. While conventional medicine historically categorised CFS as medically unexplained or even psychosomatic, the 2015 Institute of Medicine report — and subsequent NIH research funding — definitively established its physiological basis. Functional medicine’s role is not to replace conventional care but to go deeper: to identify the specific biological abnormalities (viral triggers, mitochondrial dysfunction, gut dysbiosis, toxic exposures, hormonal imbalances) driving the condition in each individual patient, and to address them systematically rather than managing symptoms in isolation.
ME/CFS affects an estimated 836,000 to 2.5 million Americans, with women affected four to five times more frequently than men. Peak onset occurs in the 30s and 40s, though the condition can develop at any age. Approximately 25% of patients are severely affected — meaning they are housebound or bedbound for significant periods. Despite its profound impact, roughly 91% of people with ME/CFS remain undiagnosed, in part because standard blood panels are routinely normal, and physicians without functional medicine training may not know which specific tests to order.
The hypothalamic-pituitary-adrenal axis is the body’s master stress-response system, coordinating cortisol release from the adrenal glands. In ME/CFS, the axis shows blunted morning cortisol secretion, flattened 24-hour rhythm, and impaired stress reactivity — leaving patients without adequate physiological drive for energy, inflammation control, and cognitive function.
Mitochondria are the ATP-generating power plants of every cell. In ME/CFS patients, multiple studies have identified abnormalities in oxidative phosphorylation, impaired Complex I electron transport chain activity, and altered metabolite profiles (raised succinate, reduced NAD+), consistent with impaired cellular energy production — the likely driver of the characteristic exhaustion and post-exertional malaise.
The autonomic nervous system (ANS) regulates heart rate, blood pressure, digestion, and vascular tone without conscious control. Many ME/CFS patients show measurable ANS dysfunction — particularly reduced parasympathetic (vagal) tone and sympathetic hyperactivation — manifesting as orthostatic intolerance, tachycardia on standing (POTS), and impaired heart rate variability (HRV).
ME/CFS produces symptoms across multiple body systems because the underlying dysfunction — mitochondrial, immune, autonomic, and hormonal — affects virtually every organ. The breadth of symptoms is why patients so often receive multiple different diagnoses before the underlying ME/CFS is recognised.
A distinctive and defining symptom: worsening of all ME/CFS symptoms 12–48 hours after physical or cognitive exertion, driven by an inability to adequately restore cellular ATP following energy expenditure.
Not tiredness that sleep resolves — patients wake feeling as exhausted as before sleep, due to blunted growth hormone pulsatility during deep sleep stages and ongoing mitochondrial insufficiency.
Polysomnography studies show ME/CFS patients have disrupted slow-wave (deep) sleep architecture and abnormal alpha-wave intrusion into NREM sleep, preventing cellular repair and memory consolidation.
Paradoxically, some patients sleep 10–14 hours yet remain exhausted; others struggle to fall or stay asleep despite profound fatigue — reflecting circadian rhythm dysregulation driven by HPA axis and melatonin pathway disruption.
Following overexertion, patients experience 24–72 hour "crashes" with a full-body return of all symptoms — caused by inflammatory cytokine surges and oxidative stress triggered by metabolic overloading of impaired mitochondria.
Impaired short-term memory, slow processing speed, word-finding difficulties, and inability to concentrate — driven by neuroinflammation, impaired cerebral blood flow, and reduced glucose availability to neurons.
Tension-type or migrainous headaches are common, often linked to autonomic vascular dysregulation, magnesium deficiency, and elevated substance P in the cerebrospinal fluid of ME/CFS patients.
Central sensitisation — a lowering of neural pain and sensory thresholds in the spinal cord and brain stem — makes ordinary stimuli (fluorescent light, background noise) feel physically painful or overwhelming.
Patients frequently lose words mid-sentence and struggle to retain new information; neuroimaging research has documented reduced white matter integrity and glucose hypometabolism in the prefrontal cortex.
Anxiety, irritability, and emotional dysregulation arise from disrupted serotonin and GABA neurotransmitter balance, driven by gut dysbiosis, vitamin B6 depletion, and chronic HPA axis hyperactivation.
Muscle pain, joint aching, and tenderness without objective inflammation — attributed to mitochondrial energy deficiency in muscle fibres, impaired lactic acid clearance, and central pain sensitisation.
Frequent pharyngeal inflammation driven by immune activation, elevated inflammatory cytokines (particularly interferon-alpha), and chronic reactivation of latent Epstein-Barr virus (EBV) in the pharyngeal lymphoid tissue.
Cervical and axillary lymphadenopathy reflects persistent immune activation and ongoing attempts by the lymphatic system to manage chronic viral or inflammatory burden.
IBS-like symptoms (bloating, altered bowel habits, nausea) are present in 60–90% of ME/CFS patients, linked to small intestinal bacterial overgrowth (SIBO), reduced gut microbiome diversity, and autonomic impairment of gut motility.
Impaired NK cell cytotoxic function — documented in multiple ME/CFS research cohorts — reduces the immune system's ability to clear viral-infected cells, leading to more frequent and prolonged infections.
Upon standing, blood pools in the lower extremities and is not adequately redistributed, causing dizziness, palpitations, and pre-syncope — driven by autonomic nervous system dysfunction and reduced blood volume common in ME/CFS.
Reduced heart rate variability and sympathetic nervous system hyperactivation produce resting tachycardia, chest tightness, and exercise intolerance in ME/CFS patients even in the absence of structural cardiac pathology.
Patients often cannot maintain normal core temperature, experiencing chills, low-grade fever, or excessive sweating — reflecting impaired hypothalamic thermoregulation and blunted cortisol response to temperature stress.
In women, ME/CFS frequently worsens premenstrually and around menopause, when oestrogen fluctuations interact with the already-compromised HPA axis, further disrupting cortisol rhythm, mitochondrial function, and immune regulation.
Multiple chemical sensitivity (MCS) — reactions to perfumes, cleaning products, or foods — is common in ME/CFS, driven by impaired Phase II liver detoxification, mast cell activation, and a sensitised central nervous system.
ME/CFS does not have formal consensus staging in the way some diseases do, but clinicians use a four-level severity classification — derived from the World Health Organization’s disability categories and the ME Association’s clinical guidance — to guide treatment intensity, pacing protocols, and realistic recovery expectations. Understanding your stage matters because treatment that is appropriate for a mild-stage patient can cause severe harm (through post-exertional malaise) in a severe-stage patient.
Patients at this stage can function and maintain employment or daily activities, but typically have reduced activity level by approximately 50% compared to pre-illness baseline. Recovery from activity takes longer than expected. Many patients at this stage have not yet received a diagnosis and are managing with willpower and lifestyle accommodations. Functional medicine biomarkers typically show borderline morning cortisol, mild CoQ10 deficiency, and initial signs of gut dysbiosis. Early intervention at this stage carries the best prognosis for full recovery.
generally not sustainable. Patients experience clear post-exertional malaise within 12–24 hours of any significant effort, rest extensively during the day, and have significant sleep disruption. Cognitive impairment becomes more disabling. Biomarkers characteristically show flattened diurnal cortisol, measurably reduced NK cell cytotoxicity, elevated inflammatory cytokines, and detectable mitochondrial metabolic abnormalities on Organic Acids Testing. This is the most common severity stage seen at presentation in a functional medicine clinic.
Patients are largely housebound, unable to leave home except for medical appointments, and spend most of the day in bed or resting. Showering, meal preparation, or brief conversation can trigger multi-day crashes. Orthostatic intolerance is typically prominent — many patients cannot sit upright for more than a few minutes without symptom escalation. Biomarkers show severely depleted DHEA-S and ACTH reserves, marked autonomic dysfunction on tilt-table or NASA Lean Test, and significant mitochondrial impairment. Treatment must be extremely cautious and paced; standard exercise prescriptions are contraindicated and harmful at this stage.
A small percentage of patients are bedbound, unable to tolerate any activity, light, or sound, and require assistance with all basic functions. Swallowing difficulties, profound cognitive impairment, and sensitivity to the point of being unable to speak above a whisper are documented in this population. Parenteral nutrition may be required in extreme cases. This stage represents the most severe end of the ME/CFS spectrum and requires medical supervision in a specialist setting. The functional medicine approach at this stage focuses on intensive nutritional support, immune modulation, and careful identification of any reversible trigger (such as active reactivated EBV or mycotoxin burden) that may be sustaining severity.
ME/CFS is almost never caused by a single trigger in isolation. Research consistently points to a multi-hit model: a susceptible biology — shaped by genetics, prior exposures, and physiological vulnerabilities — is pushed into a disease state by one or more triggering events. Identifying which specific combination of causes is active in each patient is the foundation of functional medicine’s personalised treatment approach.
Epstein-Barr virus (EBV), Human Herpesvirus-6 (HHV-6), enteroviruses, and SARS-CoV-2 are the most documented infectious triggers; “Long COVID” is now recognised as a post-viral ME/CFS-like syndrome in many patients.
Chronic stress, trauma, or an acute stressor can reset the HPA axis to a lower cortisol set-point, impairing the body’s ability to generate energy, manage inflammation, and respond to physiological demands — a pattern measurable on 4-point salivary cortisol testing.
Reduced microbiome diversity, small intestinal bacterial overgrowth (SIBO), and intestinal permeability (“leaky gut”) generate systemic lipopolysaccharide (LPS) endotoxin translocation — a potent driver of the chronic low-grade immune activation seen in ME/CFS.
Biotoxins from water-damaged buildings (particularly trichothecenes, ochratoxin A, and aflatoxin) disrupt mitochondrial function, suppress NK cell activity, and cause neurological symptoms clinically indistinguishable from ME/CFS. Mould illness is an underdiagnosed ME/CFS trigger.
Hashimoto’s thyroiditis, subclinical hypothyroidism, and impaired T4-to-T3 conversion produce fatigue, brain fog, and sleep disruption that is mechanistically identical to and frequently co-exists with ME/CFS, often undetected by TSH-alone screening.
Intracellular deficiencies of magnesium, CoQ10, vitamin D3, methylcobalamin (B12), active folate (5-MTHF), and iron compromise every aspect of cellular energy production, immune function, and neurotransmitter synthesis.
Mercury, lead, and cadmium accumulate in mitochondria and enzyme active sites, directly inhibiting ATP synthesis (particularly via Complex I and III inhibition), depleting glutathione, and generating oxidative stress disproportionate to exposure.
MTHFR C677T and A1298C variants impair folate metabolism and methylation — the biochemical process underpinning neurotransmitter production, DNA repair, detoxification, and mitochondrial function — creating a biological vulnerability to ME/CFS onset.
Elevated anti-nuclear antibodies (ANA), anti-beta-2 glycoprotein antibodies, and reduced regulatory T-cell function are documented in subsets of ME/CFS patients, suggesting an autoimmune component driving persistent immune activation and neuroinflammation.
Low progesterone, oestrogen dominance, or declining sex hormones at perimenopause create HPA axis instability that mirrors and amplifies ME/CFS pathophysiology — explaining the 4:1 female-to-male prevalence ratio and the characteristic worsening in the luteal phase and around menopause.
Sustained psychological stress (including childhood adversity and PTSD) produces epigenetic changes in HPA axis gene expression that lower the cortisol set-point and impair immune regulation, creating a biological terrain in which ME/CFS can develop following a secondary trigger.
ME/CFS shares significant symptom overlap with several other conditions, and many patients carry multiple simultaneous diagnoses before the underlying picture becomes clear. This table provides the key clinical distinctions that allow a thorough functional medicine evaluation to identify what is driving your symptoms.
| Feature | ME/CFS | Fibromyalgia | Adrenal Fatigue | Hypothyroidism |
|---|---|---|---|---|
| Hallmark symptom | Post-exertional malaise (PEM) | Widespread musculoskeletal pain & tender points | Afternoon energy crash; salt/stimulant craving | Cold intolerance; weight gain; hair loss |
| Key biomarker | Reduced NK cell cytotoxicity; mitochondrial metabolite abnormalities | Central sensitisation (elevated substance P in CSF) | Flattened 24hr salivary cortisol curve; low DHEA-S | Elevated TSH; low Free T3; elevated TPO antibodies |
| Best diagnostic test | Organic Acids Test (OAT) + NK function panel | 2016 ACR fibromyalgia diagnostic criteria exam | 4-point salivary cortisol + DHEA-S panel | Comprehensive thyroid panel (TSH, fT3, fT4, rT3, TPO-Ab) |
| Standard blood test detection | Often completely normal (CBC, CMP, TSH) | Often normal; elevated CRP in subset | Often normal; AM serum cortisol may be low-normal | Abnormal TSH in overt cases; normal in subclinical |
| Treatment approach | Mitochondrial support, pacing, LDN, IV nutrients | Central sensitisation management; duloxetine; movement therapy | Adaptogenic herbs; adrenal glandulars; stress reduction | Thyroid hormone optimisation (T4 ± T3); dietary iodine |
| Overlap with ME/CFS | — | 30–70% of ME/CFS patients also meet fibromyalgia criteria | HPA axis dysfunction is a core component of ME/CFS | Present as a co-driver in 30–40% of ME/CFS presentations |
Clinical note: The most clinically important overlap is between ME/CFS and adrenal fatigue — in functional medicine, HPA axis dysfunction is not a separate diagnosis but a core biological feature of ME/CFS itself. Testing and treating both simultaneously, as part of a single integrated protocol, produces significantly better outcomes than addressing them sequentially.
ME/CFS occupies a complex and evolving position in medicine. While its legitimacy as a physiological disease is now formally established by major health organisations, significant gaps remain in how it is diagnosed, managed, and funded — and many patients continue to be dismissed or misdiagnosed within the conventional care system. Understanding both perspectives helps you navigate your own care more effectively.
Patients Medical’s Position: We treat ME/CFS as the serious neuroimmune disease it is. We neither dismiss it as psychological nor accept that patients must simply manage indefinitely without improvement. Our clinical experience at Patients Medical NYC, spanning thousands of ME/CFS and CFS-related evaluations, confirms that when the underlying biological drivers are systematically identified and addressed, meaningful recovery is achievable for the majority of patients — particularly when treatment begins before severe chronicity sets in. We do not offer false hope; we offer evidence-informed, precision-medicine investigation and treatment.
Standard primary care blood panels almost universally return normal in ME/CFS patients — which is precisely why patients spend years undiagnosed. Our diagnostic approach uses specialised functional testing to map the specific biological dysfunctions driving your symptoms, providing a clear, actionable picture that standard care cannot offer.
This test measures cortisol levels at four points across the day (waking, noon, 4pm, bedtime) to map your HPA axis rhythm. ME/CFS patients characteristically show low morning cortisol, a flat curve lacking the normal diurnal rise-and-fall pattern, and reduced DHEA-S — providing objective evidence of adrenal insufficiency that a single morning blood cortisol test misses entirely.
The Organic Acids Test measures over 70 metabolic markers in urine, including the Krebs cycle intermediates (succinate, fumarate, malate, citrate) that directly reveal mitochondrial energy production efficiency. Elevated succinate and fumarate with reduced ATP-related metabolites provide objective evidence of the mitochondrial dysfunction driving ME/CFS fatigue. The OAT also assesses neurotransmitter metabolism, gut dysbiosis markers, and oxidative stress.
A TSH-only thyroid test misses the two most common thyroid pathologies in ME/CFS: Hashimoto’s autoimmune thyroiditis (detected by TPO and thyroglobulin antibodies) and impaired T4-to-T3 conversion (detected by low Free T3 and elevated Reverse T3 despite a normal TSH). Our comprehensive Thyroid Testing panel evaluates all five markers to ensure thyroid dysfunction is not driving or compounding your ME/CFS presentation.
These specialised tests measure intracellular (not just serum) levels of the nutrients most critical to ME/CFS recovery: CoQ10, magnesium, B12 (methylcobalamin), active folate, vitamin D3, zinc, selenium, and essential fatty acids. Standard serum nutrient tests frequently miss intracellular deficiencies that are functionally significant. Our Vitamin & Nutrient Testing panel provides precision data for targeted repletion.
We assess Epstein-Barr virus (EBV) reactivation markers (VCA IgG/IgM, EA-D IgG, EBNA IgG), Human Herpesvirus-6 (HHV-6), cytomegalovirus (CMV), and — where clinically indicated — Borrelia burgdorferi (Lyme disease) and co-infection serology. NK cell cytotoxicity testing objectively measures immune competence. Combined with Lyme Disease Testing and Mould Testing where indicated, this panel identifies the infectious burden maintaining immune activation in your case.
Check all that apply to your current experience:
There is no single treatment for ME/CFS — because there is no single cause. Our protocol is built on a detailed analysis of each patient’s functional test results, identifying the specific biological targets driving their presentation and addressing them with a personalised, layered approach that adapts as the patient recovers.
The foundation of ME/CFS treatment is rebuilding cellular energy production capacity. We use a targeted mitochondrial support protocol guided by Organic Acids Test results, providing the specific co-factors the electron transport chain and Krebs cycle require to function efficiently. This is not generic supplementation — it is precision nutritional biochemistry.
Restoring a healthy cortisol rhythm is essential for energy, sleep, inflammation management, and immune function. Our adrenal restoration protocol uses adaptogenic botanicals and adrenal glandular support to reset the HPA axis set-point, guided by serial 4-point salivary cortisol testing to track response.
Intravenous delivery bypasses gut absorption limitations common in ME/CFS and delivers therapeutic concentrations of nutrients directly to cells. The Myers Cocktail — an infusion of high-dose magnesium, B vitamins, vitamin C, and calcium — has demonstrated significant benefit in controlled trials for ME/CFS and fibromyalgia, with many patients reporting multi-day energy improvements following infusions.
Low-dose naltrexone (1.5–4.5mg at bedtime) is an off-label treatment with a growing evidence base in ME/CFS, fibromyalgia, and other neuroinflammatory conditions. At sub-pharmacological doses, LDN modulates microglial activation, reduces pro-inflammatory cytokine production (IL-6, TNF-alpha), and enhances endorphin signalling — addressing the neuroinflammatory component of ME/CFS that conventional medicine has no approved treatments for. Many patients report significant reductions in pain, fatigue, and cognitive dysfunction within 4–12 weeks.
In women, declining or imbalanced sex hormones dramatically amplify ME/CFS severity by further destabilising HPA axis regulation and mitochondrial function. We assess oestradiol, progesterone, testosterone, DHEA, and pregnenolone with precision, and where clinically indicated, use bioidentical hormone therapy to restore the hormonal milieu that supports energy production, sleep quality, immune competence, and cognitive function.
The gut microbiome profoundly influences immune regulation, neuroinflammation (via the gut-brain axis), and nutrient absorption — all of which are compromised in ME/CFS. Our gut restoration protocol begins with comprehensive Gastrointestinal Testing (GI-MAP stool analysis and SIBO breath testing), followed by targeted treatment of dysbiosis, intestinal permeability, and microbiome diversity repletion using clinically validated probiotic species and prebiotic support.
| Month 1–2 | Comprehensive functional testing; initial protocol established. Patients often notice first improvements in sleep quality and reduction in post-exertional symptom severity within 4–8 weeks of starting targeted mitochondrial and adrenal support. |
Month 3–6 | Significant energy improvements; cognitive clarity returning; activity window expanding. Serial cortisol retesting confirms HPA axis restoration; medication adjustments made. Most patients see 30–50% functional improvement in this phase. |
| Month 6–12 | Sustained energy stabilisation; PEM threshold rising (more activity tolerated without crash). Reduction in immune symptoms (sore throat, lymph node tenderness). Hormone and micronutrient panels confirming repletion. |
| Month 12–24 | For many patients, return to near-normal daily function. Maintenance protocol established. Ongoing quarterly monitoring to ensure sustained recovery and early identification of any setbacks. |
Lifestyle practices in ME/CFS are not secondary — they are an essential component of treatment. The key is that conventional lifestyle advice (exercise more, push through tiredness) is actively harmful in ME/CFS. The practices below are specifically calibrated for the ME/CFS biology.

Pacing — staying within your current energy envelope rather than pushing through fatigue — is the single most evidence-supported lifestyle intervention for ME/CFS. Keep daily activity consistently below the threshold that triggers post-exertional malaise. Use a heart rate monitor: keep heart rate below 110 bpm (or [220 – age] × 0.6) during any physical activity. Track symptoms and energy in a daily log to identify your personal PEM threshold and plan activities accordingly.

The autonomic nervous system in ME/CFS is stuck in sympathetic (fight-or-flight) dominance. Daily 10-minute practice of 4-7-8 breathing (inhale for 4 counts, hold for 7, exhale for 8) — or heart coherence breathing at a 5-second inhale/5-second exhale ratio — measurably shifts the nervous system toward parasympathetic (rest-and-restore) dominance. Use heart rate variability (HRV) biofeedback (apps like HeartMath or Elite HRV) to quantify your progress and guide session duration.

Prioritise sleep regularity above all: wake at the same time every day (including weekends) to anchor your circadian rhythm and support cortisol awakening response. Avoid napping after 2pm (which suppresses deep sleep). Create a strictly dark, cool (65–68°F) sleep environment. Take 0.5mg melatonin (not the standard 5–10mg dose, which can backfire) 90 minutes before your target sleep time. Avoid blue light for 2 hours before bed; use blue-light-blocking glasses if evening screen use is unavoidable.

Aerobic exercise is contraindicated in ME/CFS and worsens post-exertional malaise. However, gentle, horizontal movement — supine yoga, stretching, or very gentle walking (under 10 minutes) — maintains circulation, reduces deconditioning, and supports lymphatic drainage without triggering PEM. Start with 2–3 minutes of gentle movement and expand only when 3 consecutive days show no next-day symptom exacerbation. Swimming or aquatic therapy is the highest-tolerated activity for those who can access it.

Cognitive exertion causes post-exertional malaise just as reliably as physical exertion in ME/CFS. Apply the same pacing rules to mental activity: limit sustained cognitive work (reading, screens, conversations) to 20–30 minute intervals with 10-minute rest breaks. Use text-to-speech tools and audiobooks during brain fog episodes. Reduce sensory load during crashes by using earplugs, blackout curtains, and avoiding fluorescent environments. This is energy conservation, not avoidance — it is a biological necessity, not a choice.

If mould is a trigger or contributor to your ME/CFS, the single most important lifestyle intervention is remediating or leaving the mouldy environment — no supplement protocol will be effective while exposure continues. Use a high-quality HEPA air purifier (Austin Air, IQAir) in your bedroom. Switch to fragrance-free, low-VOC cleaning and personal care products to reduce chemical sensitisation burden. Filter drinking water with a certified reverse-osmosis or Berkey filter to reduce heavy metal and pharmaceutical compound exposure.
Diet in ME/CFS is not about calories — it is about reducing the biological burden on an already-compromised immune system, supporting gut integrity, providing the raw materials for mitochondrial function, and stabilising blood glucose to avoid the cortisol spikes that further exhaust the HPA axis. These are the dietary changes with the greatest evidence base for ME/CFS recovery.
Eliminate all refined sugar and ultra-processed foods immediately. Blood glucose spikes drive cortisol surges that further exhaust the HPA axis, increase neuroinflammation, and feed gut dysbiosis — sustaining the very biological patterns that drive your fatigue. Transitioning to a nutrient-dense, low-glycaemic, anti-inflammatory diet is not optional in ME/CFS recovery; it is foundational.
ME/CFS rarely exists in isolation. These conditions frequently co-occur with or share biological mechanisms with Chronic Fatigue Syndrome, and addressing them as part of a unified treatment plan consistently produces better outcomes than treating each in isolation.
Fibromyalgia and ME/CFS co-occur in 30–70% of patients and share central sensitisation, mitochondrial dysfunction, and HPA axis dysregulation as common pathophysiological threads. Both conditions are characterised by widespread pain and unrefreshing sleep, and respond to similar root-cause treatments targeting neuroinflammation and mitochondrial energy. The key distinction is that post-exertional malaise is the defining feature of ME/CFS, while widespread musculoskeletal pain with tender points is the hallmark of fibromyalgia.
HPA axis dysregulation — clinically described as adrenal fatigue — is not a separate diagnosis from ME/CFS but a core component of it. The blunted cortisol rhythm, reduced stress response capacity, and DHEA-S depletion seen in “adrenal fatigue” are the same HPA axis abnormalities driving the energy deficit in ME/CFS. Treating the HPA axis is therefore an essential part of every ME/CFS recovery protocol.
Hashimoto’s autoimmune thyroiditis is present in approximately 30–40% of ME/CFS patients and produces fatigue, brain fog, cold intolerance, and depression — symptoms nearly identical to ME/CFS. Because TSH can remain normal in Hashimoto’s for years while antibody-mediated thyroid destruction progresses, it is routinely missed without TPO antibody testing. Untreated Hashimoto’s significantly impairs recovery from ME/CFS.
Post-COVID syndrome (Long COVID) affecting an estimated 10–35% of COVID-19 patients presents with a clinical syndrome that meets ME/CFS diagnostic criteria — post-exertional malaise, cognitive dysfunction, unrestorative sleep, and orthostatic intolerance — in the majority of affected individuals. The same functional medicine protocols used for ME/CFS (mitochondrial support, LDN, gut restoration, HPA axis therapy) are showing significant benefit in Long COVID patients.
Chronic Lyme disease and ME/CFS share overlapping presentations and may co-exist: Borrelia burgdorferi infection is a documented trigger of post-infectious ME/CFS, and the immune dysregulation, mitochondrial impairment, and cognitive dysfunction of chronic Lyme are biologically identical to those in ME/CFS. In any ME/CFS patient with a tick exposure history or outdoor activity risk, Lyme serology and clinical evaluation is an essential part of the workup.
ME/CFS produces secondary sleep disorders — unrestorative sleep, circadian rhythm disruption, and alpha-wave intrusion into deep sleep — and pre-existing sleep disorders (particularly obstructive sleep apnea) can significantly worsen ME/CFS by compounding mitochondrial oxidative stress and HPA axis dysregulation. Sleep evaluation and optimisation is an essential component of ME/CFS recovery, not merely a comfort measure.
Many people with ME/CFS wait years before seeking specialist evaluation — often because they have already been told their tests are normal, or because they worry about being dismissed. If any of the following apply to you, a comprehensive functional medicine evaluation is warranted now, not later. Early intervention consistently produces better outcomes than waiting for severity to escalate.
🚨 Seek Immediate Emergency Medical Evaluation If: You experience chest pain or pressure, severe shortness of breath at rest, sudden onset of severe headache (worst headache of your life), new neurological symptoms (one-sided weakness, facial drooping, slurred speech, sudden vision loss), or loss of consciousness. These symptoms require emergency evaluation to exclude cardiac, pulmonary, or neurological emergencies that are distinct from ME/CFS.
Patient stories below reflect individual experiences. Results vary. Names have been changed to protect privacy.
Yes. Chronic Fatigue Syndrome — formally named Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) — is a recognised, serious neuroimmune disease. The U.S. National Institutes of Health, the Centers for Disease Control and Prevention, and the Institute of Medicine all classify it as a legitimate physiological illness affecting an estimated 836,000 to 2.5 million Americans.
Research published in journals including Nature Communications and the Proceedings of the National Academy of Sciences has identified measurable biological abnormalities in patients with ME/CFS, including mitochondrial dysfunction, immune activation (particularly impaired NK cell cytotoxic function), autonomic nervous system instability, and altered cortisol rhythms. The widespread dismissal of ME/CFS as psychosomatic or a product of deconditioning is not supported by current evidence, and functional medicine has long taken these biological mechanisms seriously.
If you have been told your fatigue is “just stress” or that your tests are normal, it most likely means you have not yet had the right tests ordered. A functional medicine evaluation is designed specifically to identify the biological abnormalities that standard panels miss.
Recovery from ME/CFS is highly individual and depends on how long you have been ill, the severity of your biological dysfunction, and how comprehensively root causes are addressed. Most patients who engage a root-cause functional medicine protocol begin to notice meaningful improvements in energy, sleep quality, and cognitive clarity within 3 to 6 months of initiating targeted treatment.
Substantial recovery — defined as the ability to sustain activity without post-exertional malaise — typically takes 12 to 24 months of consistent, monitored care. Complete remission is achievable for many patients, particularly those whose ME/CFS was triggered by an identifiable event such as a viral infection, mould exposure, or a period of extreme stress.
Patients with longer disease duration (5+ years) or significant mitochondrial compromise generally require a longer treatment arc. Regular biomarker retesting every 3 months allows the physician to adapt the protocol as your physiology changes and recovers, ensuring treatment remains precisely targeted throughout the recovery journey.
ME/CFS has no single confirmatory biomarker, but a comprehensive functional medicine workup reliably identifies the biological abnormalities driving the condition. The core diagnostic panel at Patients Medical includes: (1) A 4-point salivary cortisol and DHEA-S test to map HPA axis dysfunction across the day; (2) Organic Acids Test (OAT) to measure mitochondrial energy metabolites including succinate, fumarate, and malate; (3) A comprehensive thyroid panel including TSH, Free T3, Free T4, Reverse T3, and TPO antibodies.
We also use SpectraCell or NutrEval micronutrient analysis to identify intracellular deficiencies in CoQ10, magnesium, B12, folate, and vitamin D. A full infectious disease panel including Epstein-Barr virus (EBV) reactivation markers, HHV-6, and Lyme/co-infection serology is ordered when clinically indicated.
Standard primary care blood panels (CBC, basic metabolic panel) are routinely normal in ME/CFS patients, which is precisely why so many patients remain undiagnosed for years. The right tests — applied in the right sequence by a physician experienced in ME/CFS — consistently reveal the biological picture driving the condition.
Weight gain is a common and deeply frustrating secondary consequence of ME/CFS, and it arises from several interconnected mechanisms. First, reduced physical activity — driven by post-exertional malaise that makes sustained exercise impossible — decreases total daily energy expenditure. Second, cortisol dysregulation associated with HPA axis dysfunction promotes visceral fat accumulation and insulin resistance, even in the absence of overeating.
Third, mitochondrial dysfunction impairs the liver’s ability to regulate glucose and fatty acid metabolism efficiently. Fourth, chronic low-grade inflammation elevates inflammatory cytokines (particularly TNF-alpha and IL-6), which directly disrupt leptin and ghrelin signalling — the hormones that regulate hunger and satiety. Finally, hypothyroidism, which frequently overlaps with ME/CFS, slows basal metabolic rate.
The key clinical insight is that standard calorie-restriction advice is both ineffective and potentially harmful in ME/CFS. Sustainable weight management in these patients requires first resolving the underlying metabolic and hormonal dysfunction — at which point weight often normalises naturally as energy production, cortisol rhythm, and thyroid function are restored.
ME/CFS and fibromyalgia are distinct conditions that share significant symptom overlap and frequently co-occur in the same patient. The defining feature of ME/CFS is post-exertional malaise — a characteristic worsening of all symptoms 12 to 48 hours after physical or cognitive effort. Fibromyalgia’s hallmark, by contrast, is diffuse musculoskeletal pain with specific widespread pain index and symptom severity criteria under the 2016 ACR diagnostic guidelines.
ME/CFS more prominently features autonomic dysfunction (orthostatic intolerance, POTS), immune abnormalities (reduced NK cell cytotoxicity, chronic viral reactivation), and measurable HPA axis dysregulation. Fibromyalgia is more strongly associated with central sensitisation — an amplification of pain signals in the spinal cord and brain — and is diagnosed primarily by clinical criteria rather than biomarkers.
In clinical practice, approximately 30–70% of ME/CFS patients also meet criteria for fibromyalgia. Many functional medicine protocols address both conditions simultaneously by targeting neuroinflammation, mitochondrial function, and HPA axis regulation — the shared biological pathways underlying both diagnoses.
ME/CFS produces a distinctive, paradoxical immune pattern: an overactivated innate immune response coupled with impaired adaptive immune clearance. Patients typically show elevated levels of pro-inflammatory cytokines including interferon-alpha, IL-1 beta, IL-6, and TNF-alpha, which drive the sore throat, swollen lymph nodes, and flu-like feeling that many patients describe.
Natural killer (NK) cell cytotoxic function — the immune system’s frontline defence against viral-infected cells — is consistently reduced in ME/CFS patients across multiple independent research cohorts. This impairment helps explain why many patients have chronic reactivation of latent viruses such as Epstein-Barr virus (EBV), Human Herpesvirus-6 (HHV-6), and cytomegalovirus (CMV), creating a cycle where the immune system remains activated but unable to resolve the infections driving that activation.
Functional medicine targets this immune paradox directly through low-dose naltrexone (LDN), which modulates microglial activation and reduces cytokine production; medicinal mushroom extracts (particularly AHCC and beta-glucans) that enhance NK cell function; and targeted nutritional support for immune competence, including zinc, selenium, and vitamin D3 at therapeutic levels.
Evidence-informed nutritional and botanical support for ME/CFS recovery centres on three core targets: mitochondrial energy production, HPA axis restoration, and immune modulation. For mitochondrial support, CoQ10 (300–600mg/day in ubiquinol form), D-Ribose (5g three times daily), L-Carnitine (1–2g/day), Magnesium glycinate (400–600mg/day), and alpha-lipoic acid are the most evidence-supported agents.
For adrenal and HPA axis support, adaptogenic herbs including Rhodiola rosea (SHR-5 extract), Ashwagandha (KSM-66 extract), and Panax ginseng have demonstrated benefit in clinical research, alongside phosphatidylserine for cortisol modulation. Immune modulation protocols at Patients Medical incorporate low-dose naltrexone (LDN) at 1.5–4.5mg at bedtime, which has shown significant benefit in ME/CFS, fibromyalgia, and related neuroinflammatory conditions in observational studies and small controlled trials.
B12 (particularly methylcobalamin via injection, bypassing the gut), active folate (5-MTHF), and high-dose vitamin D3 with K2 support methylation and immune regulation. All supplementation should be guided by a physician using individualised laboratory data, as many ME/CFS patients have genetic methylation variants (particularly MTHFR C677T) that affect how they utilise specific nutrient forms and dosages.
At Patients Medical, we don’t guess — we test. Our physicians use advanced functional diagnostics to identify exactly what is driving your ME/CFS, then build a personalised, root-cause treatment protocol designed to restore your energy, cognitive function, and quality of life.
Call us at (212) 794-8800 · 800 Second Avenue, Suite 900, New York, NY 10017
Patients Medical specializes in gently helping the patient identify the root cause of their medical issues and then assist them to recover from their problems to help them move forward to good health.
To schedule an in person on Tele-medicine appointment, please call our office at (212) 794-8800 or email us at info@PatientsMedical.com We look forward to hearing from you
Patients Medical PC
1148 Fifth Avenue, Suite 1B New York, NY 10128
Copyright © 2025 Patients Medical. All Rights Reserved.
All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice. Statements made on this website have not been evaluated by the Food and Drug Administration. The information contained herein is not intended to diagnose, treat, cure or prevent any disease. Patients Medical.